Jena Anupam B, Goldman Dana P, Seabury Seth A
Department of Health Care Policy, Harvard Medical School, Boston, Massachusetts2Department of Medicine, Massachusetts General Hospital, Boston, Massachusetts3National Bureau of Economic Research, Cambridge, Massachusetts.
National Bureau of Economic Research, Cambridge, Massachusetts4Leonard D. Schaeffer Center for Health Policy and Economics, University of Southern California, Los Angeles.
JAMA Intern Med. 2015 Apr;175(4):617-23. doi: 10.1001/jamainternmed.2014.7886.
Human papillomavirus (HPV) vaccination rates among US females remain low, in part because of concerns that HPV vaccination may promote unsafe sexual activity by lowering perceived risks of acquiring a sexually transmitted infection (STI).
To study whether HPV vaccination of females is associated with increases in STI rates.
DESIGN, SETTING, AND PARTICIPANTS: Using a large, longitudinal insurance database of females aged 12 to 18 years insured from January 1, 2005, through December 31, 2010, in the United States, we examined whether HPV vaccination was associated with an increase in incident STIs among females who were vaccinated compared with those who were not. We defined STIs as one or more medical claims for any of the following infections in a given quarter: chlamydia, gonorrhea, herpes, human immunodeficiency virus or AIDS, or syphilis. We used difference-in-difference analysis to compare changes in STI rates among HPV-vaccinated females before and after vaccination (index quarter) to changes among age-matched nonvaccinated females before and after the index quarter. We analyzed whether effects varied according to age and prior contraceptive medication use.
Rates of STIs.
The rates of STIs in the year before vaccination were higher among HPV-vaccinated females (94 of 21 610, 4.3 per 1000) compared with age-matched nonvaccinated females (522 of 186 501, 2.8 per 1000) (adjusted odds ratio, 1.37; 95% CI, 1.09-1.71; P = .007). The rates of STIs increased for the vaccinated (147 of 21 610, 6.8 per 1000) and nonvaccinated (781 of 186 501, 4.2 per 1000) groups in the year after vaccination (adjusted odds ratio, 1.50; 95% CI, 1.25-1.79; P < .001). The difference-in-difference odds ratio was 1.05 (95% CI, 0.80-1.38; P = .74), implying that HPV vaccination was not associated with an increase in STIs relative to growth among nonvaccinated females. Similar associations held among subgroups aged 12 through 14 years and aged 15 through 18 years and among females with contraceptive use in the index quarter.
Human papillomavirus vaccination was not associated with increases in STIs in a large cohort of females, suggesting that vaccination is unlikely to promote unsafe sexual activity.
美国女性人乳头瘤病毒(HPV)疫苗接种率仍然很低,部分原因是担心HPV疫苗接种可能通过降低对感染性传播感染(STI)风险的认知而助长不安全的性行为。
研究女性HPV疫苗接种是否与性传播感染率上升有关。
设计、背景和参与者:利用一个大型纵向保险数据库,该数据库涵盖了2005年1月1日至2010年12月31日在美国投保的12至18岁女性,我们研究了接种HPV疫苗的女性与未接种疫苗的女性相比,是否与性传播感染发病率增加有关。我们将性传播感染定义为在给定季度中针对以下任何一种感染的一项或多项医疗索赔:衣原体、淋病、疱疹、人类免疫缺陷病毒或艾滋病,或梅毒。我们使用差异分析来比较接种HPV疫苗的女性在接种前后(索引季度)性传播感染率的变化与年龄匹配的未接种疫苗女性在索引季度前后的变化。我们分析了影响是否因年龄和先前使用的避孕药物而有所不同。
性传播感染率。
与年龄匹配的未接种疫苗女性(186501人中的522人,每1000人中有2.8人)相比,接种HPV疫苗的女性在接种前一年的性传播感染率更高(21610人中的94人,每1000人中有4.3人)(调整后的优势比为1.37;95%置信区间为1.09-1.71;P = 0.007)。接种疫苗的组(21610人中的147人,每1000人中有6.8人)和未接种疫苗的组(186501人中的781人,每1000人中有4.2人)在接种后一年的性传播感染率均有所上升(调整后的优势比为1.50;95%置信区间为1.25-1.79;P < 0.001)。差异分析的优势比为1.05(95%置信区间为0.80-1.38;P = 0.74),这意味着与未接种疫苗的女性的增长相比,HPV疫苗接种与性传播感染的增加无关。在12至14岁和15至18岁的亚组以及索引季度使用避孕药具的女性中也有类似的关联。
在一大群女性中,人乳头瘤病毒疫苗接种与性传播感染的增加无关,这表明疫苗接种不太可能助长不安全的性行为。